Intellia setback adds on-target tox to gene editing safety debate: Clinical Report

Intellia’s trial pause drove the biggest share price drop of the week, while Inhibrx was the biggest gainer, doubling in value after ozekibart showed benefit in a registrational trial to treat chondrosarcoma.

On Monday, Intellia Therapeutics Inc. (NASDAQ:NTLA) announced it was voluntarily pausing dosing in its Phase III MAGNITUDE and MAGNITUDE-2 Phase III trials of in vivo ATTR CRISPR gene therapy nex-z, also known as nexiguran ziclumeran, after a patient experienced a Grade 4 liver tox event...